TSG News Banner World Map

EPA Develops Guidance for Disinfectant Product Use Against Ebola Virus (October 2014)

EPA has worked closely with the Center for Disease Control (CDC) to develop interim guidance for Ebola virus infection control in hospitals. Although there are no EPA-registered products with specific claims against the Ebola virus, the Ebola virus is susceptible to a broad range of hospital disinfectants because it is an enveloped virus. In contrast, non-enveloped viruses are more resistant to disinfectants. However, given the apparent low infectious dose, potential of high virus titers in the blood of ill patients and disease severity, EPA and CDC are taking additional precautions by recommending the use of disinfectants with a higher potency than typically required to inactive an enveloped virus.

Specifically, EPA-registered hospital disinfectants with claims against non-enveloped viruses are being prescribed due to their broad antiviral capabilities. These disinfectants are capable of inactivating both enveloped and non-enveloped viruses, and may be used to disinfect surfaces in rooms of patients with infectious diseases.

At this time, EPA is not allowing label claims related to product efficacy specifically against the Ebola virus. If a registrant has EPA-registered products that meet CDC guidance criteria, they may identify such products through company websites or other non-label communications. These communications should include that:

    ▲ The product meets the CDC criteria for disinfectant products with label claims for a non-enveloped virus;

    ▲ The product is intended for use on hard, non-porous surfaces; and

    ▲ The product’s label use instructions for the non-enveloped virus or viruses should be followed.

More Information
The CDC Guidance Document
EPA Ebola Guidance
Disinfectants for Use Against Ebola
Contact TSG








share button Share to LinkedIn Share to Twitter Share to Facebook Share to Google+ Share to Email

Follow Us on LinkedIn
 TSG Logo
 Homepage Link      Email This Page Print this Page










Subscribe to email advisories View all TSG advisories